Optimizing the Implementation of Novel Diagnostic Tests for Prostate, Lung, and Colon Cancer
Principal Investigator
Name
Grant Langseth
Institution
OncoCellMDx
Position Title
Principle Investigator
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-185
Initial CDAS Request Approval
Dec 29, 2015
Title
Optimizing the Implementation of Novel Diagnostic Tests for Prostate, Lung, and Colon Cancer
Summary
In the last three years, the number of publications referencing novel diagnostic tests for prostate, lung, and colon cancer has increased exponentially. This is largely due to the dramatic decrease in costs of next-generation sequencing and an increased emphasis on creating a more efficient healthcare system that minimizes unnecessary treatment and expenditure. While a substantial amount of information has been published surrounding the nature of these new tests, most performance characteristics are reported inside the limited context of a controlled sample population, making it hard to predict what the true impact of the test would be if used in the clinical setting. I propose to combine the data from the PLCO dataset with the latest studies on nascent diagnostic tests to help determine which tests are best suited to save lives and generate system-wide savings.
Aims
-Rank nascent diagnostic tests for prostate, lung, and colon cancer according to the potential number of lives saved and total unnecessary procedures avoided.
-Highlight the specific areas in both the screening and monitoring market in greatest need of updated diagnostic technology.
Collaborators
Geoffrey Erickson